Loading…
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-43M | $-15M | $-33M | -25.0% | - | -75.5% |
| 2024 | $0M | $-27M | $-62M | $-25M | -191.3% | - | 130.5% |
| 2023 | $0M | $-23M | $-27M | $-24M | -69.9% | - | -34.6% |
| 2022 | $0M | $-32M | $-41M | $-27M | -73.6% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 32.56 | 23.41 | 27.55 | 42.97 |
| Research And Development | - | 24.47 | 16.53 | 19.39 | 33.72 |
| Selling General And Administration | - | 8.10 | 6.88 | 8.16 | 9.25 |
| Total Expenses | - | 32.56 | 23.41 | 27.55 | 42.97 |
| Operating Income | - | -32.56 | -23.41 | -27.55 | -42.97 |
| Total Operating Income As Reported | - | -32.56 | -23.41 | -27.55 | -42.97 |
| EBITDA | - | -32.20 | -23.26 | -27.46 | -42.87 |
| Normalized EBITDA | - | -32.22 | -23.26 | 5.91 | -70.01 |
| EBIT | - | -32.56 | -23.41 | -27.55 | -42.97 |
| Interest Income | - | 0.65 | 1.58 | 1.82 | 2.50 |
| Interest Expense | 0.02 | - | - | - | - |
| Net Interest Income | - | 0.65 | 1.58 | 1.82 | 2.50 |
| Other Non Operating Income Expenses | 0.24 | 0.59 | 0.08 | - | - |
| Other Income Expense | - | -9.40 | -5.21 | -36.57 | 25.18 |
| Interest Income Non Operating | - | 0.65 | 1.58 | 1.82 | 2.50 |
| Interest Expense Non Operating | 0.02 | - | - | - | - |
| Net Non Operating Interest Income Expense | - | 0.65 | 1.58 | 1.82 | 2.50 |
| Pretax Income | - | -41.31 | -27.03 | -62.29 | -15.28 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -41.31 | -27.03 | -62.29 | -15.28 |
| Net Income From Continuing And Discontinued Operation | - | -41.31 | -27.03 | -62.29 | -15.28 |
| Net Income From Continuing Operation Net Minority Interest | - | -41.31 | -27.03 | -62.29 | -15.28 |
| Net Income | - | -41.31 | -27.03 | -62.29 | -15.28 |
| Net Income Common Stockholders | - | -41.31 | -27.03 | -62.29 | -15.28 |
| Net Income Including Noncontrolling Interests | - | -41.31 | -27.03 | -62.29 | -15.28 |
| Normalized Income | - | -41.33 | -27.03 | -28.92 | -42.42 |
| Diluted NI Availto Com Stockholders | - | -41.31 | -27.03 | -62.29 | -15.28 |
| Basic Average Shares | 41.85 | 46.55 | 48.03 | 60.99 | - |
| Diluted Average Shares | 41.85 | 46.55 | 48.03 | 60.99 | - |
| Reconciled Depreciation | - | 0.37 | 0.15 | 0.08 | 0.10 |
| Total Unusual Items | - | 0.02 | 0 | -33.37 | 27.14 |
| Total Unusual Items Excluding Goodwill | - | 0.02 | 0 | -33.37 | 27.14 |
| Special Income Charges | - | 0.02 | 0 | 0 | 0 |
| Gain On Sale Of Security | - | - | - | -33.38 | 27.14 |
| General And Administrative Expense | - | 8.10 | 6.88 | 8.16 | 9.25 |
| Other Gand A | - | 8.10 | 6.88 | 8.16 | 9.25 |
| Gain On Sale Of Ppe | - | 0.02 | 0 | 0 | 0 |
| Total Other Finance Cost | 0.02 | -0.65 | -1.58 | - | - |
| Earnings From Equity Interest | - | -10.01 | -5.28 | -3.20 | -1.96 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc.this co. | CRVS | $986M | -64.49 | 16.10 | -25.0% | -22.91 |
| QuidelOrtho Corporation | QDEL | $1.0B | -0.92 | 0.54 | -58.9% | -7.68 |
| EyePoint, Inc. | EYPT | $1.0B | -4.43 | 3.36 | -75.8% | -4.13 |
| Artivion, Inc. | AORT | $1.0B | 103.65 | 2.26 | 2.2% | 18.87 |
| InnovAge Holding Corp. | INNV | $977M |
| - |
| - |
| - |
| - |
| - |
| -32.24 |
| 4.16 |
| -12.9% |
| -102.40 |
| U.S. Physical Therapy, Inc. | USPH | $940M | 62.41 | 1.97 | 3.2% | 11.12 |
| Anteris Technologies Global Corp. | AVR | $939M | - | 48.67 | -238.4% | - |
| Olema Pharmaceuticals, Inc. | OLMA | $933M | -5.74 | 1.95 | -33.9% | -4.99 |
| Nutex Health Inc. | NUTX | $930M | 13.13 | 2.82 | 21.5% | 3.81 |
| Peer Median | - | -0.92 | 2.54 | -23.4% | -4.13 | |